Faculty

Institution

Unit

Venue

Susan Lattimore

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Center Of Ohsu Hemostasis And Thrombosis

NoneSusan Lattimore is currently serving as a Center Of Ohsu Hemostasis And Thrombosis faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Susan Lattimore

Oregon Health & Science University

You can click a keyword to filter the displayed items

hematology medicine hemostasis health sciences thrombosis gene therapy clinical trials laboratory medicine etranacogene dezaparvovec immunology bleeding disorders genetics clinical research pharmacotherapy gene transfer translational medicine outcomes research human genetics women's health virus research antiviral research enzyme inhibition antiviral therapy viral hepatitis enhanced vector year data adolescent women heavy menstrual bleeding bone marrow transplantation intensive care strategic studies health planning medicinal research avian biology obstetrics and gynaecology regional studies medical virology general virology biological therapies novel therapies coagulopathy treatment and prevention neonatology integrated care connected health research-practice partnerships hematological malignancies medical decision making pharmacokinetics hla typing case studies benchmark studies gene vector adolescent medicine anticoagulants cohort studies prospective cohort studies short-term variability retrospective cohort studies clinical evidence inhibitory activity host factors hemophilia b bleed cessation neonatal platelet adhesion goal attainment care centers rare coagulation disorders united states hemophilia patient care inherited bleeding disorders health services research priorities

Notable Scholarly Works

Notable Federal Grants

Collaborators

Completion of Phase 2B Trial of Etranacogene Dezaparvovec Gene Therapy in Patients With Hemophilia B Over 5 Years. Blood Advances (2025)

medicinehematologythrombosispharmacotherapybleeding disordersclinical trialsclinical researchhemostasis

End-Of-Study Analysis of the Hope-B Trial Confirms the Durable Efficacy and Safety of Etranacogene Dezaparvovec Hemophilia B Gene Therapy Over 5 Years. Blood (2025)

medicinehematologybleeding disorderspharmacotherapyclinical trials

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine (2025)

medicinepathogenesishematologythrombosispharmacotherapybleeding disordersclinical researchpathologyhemostasis

Htrs2025.P1.4 Current Clinical Practices in Htcs for Identifying, Classifying and Providing Care to Hemophilia Carriers. Research and Practice in Thrombosis and Haemostasis (2025)

Htrs2025.P2.55 Patient Satisfaction at United States Hemophilia Treatment Centers in 2023. Research and Practice in Thrombosis and Haemostasis (2025)

Management of Hemophilia and Hemophilia Carriers. Blood (2025)

Adults With Severe or Moderately Severe Haemophilia B Receiving Etranacogene Dezaparvovec in the Hope-B Phase 3 Trial Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Haemostatic Protection After 24 Months’ Follow-Up. Hämostaseologie (2023)

W S PipeWG F LeebeekM RechtS N KeyS LattimoreG CastamanM CoppensD CooperR GutS SlawkaS VerweijR DolmetschY LiPE MonahanW Miesbach

immunologydermatologyhematologydurable haemostatic protectioncritical careetranacogene dezaparvovechemostasis

Building the Foundation for a Community-Generated National Research Blueprint for Inherited Bleeding Disorders: Research Priorities in Health Services; Diversity, Equity, and Inclusion; and Implementation Science. Expert Review of Hematology (2023)

Vanessa R. ByamsJudith R. BakerCindy BaileyNathan T. ConnellMelissa S. CrearyRandall G. CurtisAlexis DinnoChristine J. GuelcherMichelle KimRoshni KulkarniSusan LattimoreKeri L. NorrisLucy RamirezMark W. SkinnerSusan SymingtonPatricia TobaseEsmeralda VázquezBeth B. WarrenEmily WheatTyler W. Buckner

hematological malignanciesresearch prioritiescommunity-engaged researchpublic healthhealth equityhealth planninghematologythrombosisconnected healthbleeding disordersqualitative researchinherited bleeding disordershealth policydermatologylaboratory medicineimplementation researchhemostasisstrategic studieshealth servicesresearch-practice partnershipsintensive care

Durability of Bleeding Protection and Factor IX Activity in Individuals With and Without Adeno-Associated Virus Serotype 5 Neutralising Antibodies (Titres 1: 700) in the Phase 3 Hope-B Trial of Etranacogene Dezaparvovec Gene Therapy for Haemophilia B. Hämostaseologie (2023)

W S PipeWG F LeebeekM RechtS N KeyS LattimoreG CastamanD CooperS VerweijR DolmetschJ TarrantY LiE P MonahanW Miesbach

gene therapygeneral virologyclinical evidenceneutralising antibodiesinhibitory activityhivantiviral researchhematologyhost factorsantiviral therapyviral hepatitisdermatologymedical virologyimmunologyvirus researchgene expressionpharmacologyenzyme inhibitionhope-b trialvirologyfactor ix activity

Gene Therapy With Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine (2023)

Steven W. PipeFrank W.G. LeebeekMichael RechtNigel S. KeyGiancarlo CastamanWolfgang MiesbachSusan LattimoreKathelijne PeerlinckPaul Van der ValkMichiel CoppensPeter KampmannKarina MeijerNiamh O’ConnellK. John PasiDaniel P. HartRashid KazmiJan AstermarkCedric R.J.R. HermansRobert KlamrothRichard LemonsNathan VisweshwarAnnette von DrygalskiGuy YoungShelley E. CraryMiguel EscobarEsteban GomezRebecca Kruse-JarresDoris V. QuonEmily SymingtonMichael WangAllison P. WheelerRobert GutYing P. LiuRicardo E. DolmetschDavid L. CooperYanyan LiBrahm GoldsteinPaul E. Monahan

gene therapymedicinehemophilia bhematologymolecular medicinethrombosisnovel therapiesbiological therapiesbleeding disordersetranacogene dezaparvovecbone marrow transplantationcoagulopathypathologytranslational medicinehemostasis

1
2
3
10 / page

Susan Lattimore

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Center Of Ohsu Hemostasis And Thrombosis

NoneSusan Lattimore is currently serving as a Center Of Ohsu Hemostasis And Thrombosis faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Susan Lattimore

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Completion of Phase 2B Trial of Etranacogene Dezaparvovec Gene Therapy in Patients With Hemophilia B Over 5 Years. Blood Advances (2025)

medicinehematologythrombosispharmacotherapybleeding disordersclinical trialsclinical researchhemostasis

End-Of-Study Analysis of the Hope-B Trial Confirms the Durable Efficacy and Safety of Etranacogene Dezaparvovec Hemophilia B Gene Therapy Over 5 Years. Blood (2025)

medicinehematologybleeding disorderspharmacotherapyclinical trials

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine (2025)

medicinepathogenesishematologythrombosispharmacotherapybleeding disordersclinical researchpathologyhemostasis

Htrs2025.P1.4 Current Clinical Practices in Htcs for Identifying, Classifying and Providing Care to Hemophilia Carriers. Research and Practice in Thrombosis and Haemostasis (2025)

Htrs2025.P2.55 Patient Satisfaction at United States Hemophilia Treatment Centers in 2023. Research and Practice in Thrombosis and Haemostasis (2025)

Management of Hemophilia and Hemophilia Carriers. Blood (2025)

W S PipeWG F LeebeekM RechtS N KeyS LattimoreG CastamanM CoppensD CooperR GutS SlawkaS VerweijR DolmetschY LiPE MonahanW Miesbach

immunologydermatologyhematologydurable haemostatic protectioncritical careetranacogene dezaparvovechemostasis

W S PipeWG F LeebeekM RechtS N KeyS LattimoreG CastamanD CooperS VerweijR DolmetschJ TarrantY LiE P MonahanW Miesbach

Gene Therapy With Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine (2023)

1
2
3
10 / page